Clinical Trials | April 30, 2026
Pfizer drug delivers breakthrough in late-stage blood cancer trial
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
After Phase 3 results show major hair regrowth gains
Avio Smart Market Stack Limited and Huwel Lifesciences unveil portable, cost-efficient molecular testing platform
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
Subscribe To Our Newsletter & Stay Updated
